Dehydroevodiamine HCl

ID: dehydroevodiamine_hcl

Aliases: dehydroevodiamine hydrochloride, DHED

Type: compound

Route/form: oral or route depends on studied product

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic

Source types: preclinical

Linked sources: 3

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• memory-impaired rat models
• cholinergic/neuroprotective hypotheses

Optimization domains

• cognitive support
• memory
• natural product derivative

Research basis

• Preclinical rat work reports improved cognitive function in memory-impaired models.
• A useful older natural-product-derived nootropic lead for the graph.

Limits, risks, and missing evidence

• Rodent impairment models do not establish healthy-human memory benefit.
• Exact CNS target profile and safety margin need better curation.

Risk flags

• preclinical only
• limited human data
• CNS unknowns
• identity and dose curation

Linked papers, labels, and reviews

1. Dehydroevodiamine HCl enhances cognitive function in memory-impaired rat models
   preclinical / pubmed_dehydroevodiamine_hcl_2017
   Scopolamine and Abeta-infused rat cognition models.
2. Dehydroevodiamine.HCl prevents impairment of learning and memory and neuronal loss in rat models of cognitive disturbance
   preclinical / pubmed_dehydroevodiamine_memory_2000
   Earlier rat cognitive-disturbance source for DHED memory and neuronal-loss claims.
3. Dehydroevodiamine HCl Improves Stress-Induced Memory Impairments and Depression Like Behavior in Rats
   preclinical / pmc_dehydroevodiamine_stress_2014
   Additional rat behavioral source; useful for stress-linked memory context, still non-human.